Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 07, 2020
Proxygen’s unique molecular glue degrader discovery platform complements Boehringer Ingelheim’s focus on proteolysis targeting chimeras (PROTACs) in the aim of degrading cancer drivers that were previously considered undruggable.